

Karl Philip Claxton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8139725/publications.pdf>

Version: 2024-02-01

69
papers

6,673
citations

147801

31
h-index

106344

65
g-index

70
all docs

70
docs citations

70
times ranked

7412
citing authors

#	ARTICLE	IF	CITATIONS
1	Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics (United Kingdom), 2001, 10, 779-787.	1.7	885
2	The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics, 1999, 18, 341-364.	2.7	725
3	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value in Health, 2016, 19, 929-935.	0.3	589
4	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 2015, 19, 1-504.	2.8	536
5	A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet, The, 2002, 360, 711-715.	13.7	378
6	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics (United Kingdom), 2005, 14, 339-347.	1.7	368
7	An economic approach to clinical trial design and research priority-setting. Health Economics (United Kingdom), 2007, 16, 107-124.	1.7	316
8	Discounting in Economic Evaluations. Pharmacoeconomics, 2018, 36, 745-758.	3.3	210
9	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health, 2016, 19, 921-928.	0.3	203
10	Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health, 2018, 3, e000964.	4.7	181
11	Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ: British Medical Journal, 2008, 336, 251-254.	2.3	178
12	Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics, 2000, 17, 461-477.	3.3	172
13	Exploring Uncertainty in Cost-Effectiveness Analysis. Pharmacoeconomics, 2008, 26, 781-798.	3.3	156
14	Discounting and decision making in the economic evaluation of health-care technologies. Health Economics (United Kingdom), 2011, 20, 2-15.	1.7	156
15	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 2007, 12, 56-58.	1.7	155
16	Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Economics (United Kingdom), 1999, 8, 269-274.	1.7	112
17	OFT, VBP: QED?. Health Economics (United Kingdom), 2007, 16, 545-558.	1.7	102
18	CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?. Health Economics (United Kingdom), 2015, 24, 1-7.	1.7	88

#	ARTICLE	IF	CITATIONS
19	A Framework for Addressing Structural Uncertainty in Decision Models. <i>Medical Decision Making</i> , 2011, 31, 662-674.	2.4	72
20	The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis. <i>Medical Decision Making</i> , 2014, 34, 951-964.	2.4	67
21	Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. <i>Value in Health</i> , 2017, 20, 234-239.	0.3	64
22	The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?. <i>Medical Decision Making</i> , 2008, 28, 287-299.	2.4	60
23	Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. <i>Value in Health</i> , 2018, 21, 266-275.	0.3	58
24	Addressing Adoption and Research Design Decisions Simultaneously. <i>Medical Decision Making</i> , 2011, 31, 853-865.	2.4	52
25	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. <i>Health Economics (United Kingdom)</i> , 2017, 26, 109-123.	1.7	52
26	Eliciting Distributions to Populate Decision Analytic Models. <i>Value in Health</i> , 2010, 13, 557-564.	0.3	47
27	Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. <i>Statistics in Medicine</i> , 2011, 30, 2363-2380.	1.6	47
28	Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. <i>Value in Health</i> , 2019, 22, 995-1002.	0.3	45
29	Supporting the development of a health benefits package in Malawi. <i>BMJ Global Health</i> , 2018, 3, e000607.	4.7	42
30	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. <i>Value in Health</i> , 2016, 19, 885-891.	0.3	38
31	What next after GDP-based cost-effectiveness thresholds?. <i>Gates Open Research</i> , 2020, 4, 176.	1.1	36
32	Budget allocation and the revealed social rate of time preference for health. <i>Health Economics (United Kingdom)</i> , 2012, 21, 612-618.	1.7	32
33	Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse. <i>Medical Decision Making</i> , 2013, 33, 415-436.	2.4	32
34	Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses. <i>Value in Health</i> , 2018, 21, 715-723.	0.3	31
35	Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. <i>Health Technology Assessment</i> , 2021, 25, 1-124.	2.8	29
36	Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. <i>BMJ Open</i> , 2020, 10, e036411.	1.9	28

#	ARTICLE	IF	CITATIONS
37	Cancer Drugs Fund requires further reform. <i>BMJ, The</i> , 2016, 354, i5090.	6.0	26
38	The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. <i>Health Economics (United Kingdom)</i> , 2017, 37, 50-69.	1.7	21
39	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	1.7	23
40	How to estimate the health benefits of additional research and changing clinical practice. <i>BMJ, The</i> , 2015, 351, h5987.	6.0	21
41	Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts. <i>Medical Decision Making</i> , 2020, 40, 448-459.	2.4	18
42	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. <i>Value in Health</i> , 2015, 18, 865-875.	0.3	17
43	Accounting for Timing when Assessing Health-Related Policies. <i>Journal of Benefit-Cost Analysis</i> , 2019, 10, 73-105.	1.2	17
44	Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure. <i>Medical Decision Making</i> , 2020, 40, 170-182.	2.4	17
45	Valuing health outcomes: developing better defaults based on health opportunity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 729-736.	1.4	16
46	How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 885-903.	2.1	16
47	Redefining the analytical approach to pharmacoeconomics. <i>Journal of Health Economics</i> , 1999, 8, 187-189.		15
48	Rights, responsibilities and NICE: a rejoinder to Harris. <i>Journal of Medical Ethics</i> , 2007, 33, 462-464.	1.8	15
49	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. <i>BMJ Global Health</i> , 2020, 5, e003006.	4.7	14
50	Reference Case Methods for Expert Elicitation in Health Care Decision Making. <i>Medical Decision Making</i> , 2022, 42, 182-193.	2.4	12
51	Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. <i>BMJ Open</i> , 2021, 11, e046417.	1.9	11
52	Value-based tiered pricing for universal health coverage: an idea worth revisiting. <i>Gates Open Research</i> , 2020, 4, 16.	1.1	9
53	Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. <i>Health Policy and Planning</i> , 2022, 37, 45-54.	2.7	8
54	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2649-2666.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Appraising the value of evidence generation activities: an HIV modelling study. <i>BMJ Global Health</i> , 2018, 3, e000488.	4.7	7
56	How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework. <i>Health Economics (United Kingdom)</i> , 2018, 27, e41-e54.	1.7	5
57	Does public long-term care expenditure improve care-related quality of life of service users in England?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2561-2581.	1.7	5
58	How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 557-572.	2.1	5
59	Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 183-190.	5.0	4
60	A Cost-Effectiveness Analysis of Intradiscal Electrothermal Therapy Compared with Circumferential Lumbar Fusion. <i>Pain Practice</i> , 2018, 18, 515-522.	1.9	4
61	The Value of Further Research: The Added Value of Individual-Participant Level Data. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 273-284.	2.1	3
62	Practical metrics for establishing the health benefits of research to support research prioritisation. <i>BMJ Global Health</i> , 2020, 5, e002152.	4.7	3
63	Authors'™ Response to: "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al." by Sampson, Firth, and Towse. <i>Medical Decision Making</i> , 2021, 41, 258-260.	2.4	3
64	Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. <i>Health Economics (United Kingdom)</i> , 2018, 27, e28-e40.	1.7	2
65	Redefining the analytical approach to pharmacoeconomics. <i>Health Economics (United Kingdom)</i> , 1999, 8, 187-189.	1.7	2
66	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. <i>BMJ Global Health</i> , 2021, 6, e007047.	4.7	1
67	Linee guida di buona pratica per creare modelli analitico-decisionali nella valutazione delle tecnologie sanitarie. <i>Giornale Italiano Di Health Technology Assessment</i> , 2008, 1, 1-14.	0.1	0
68	Comment: Positive tails and normative dogs. <i>Health Economics (United Kingdom)</i> , 2018, 27, 1425-1427.	1.7	0
69	The epidemiology, management and impact of surgical wounds healing by secondary intention: a research programme including the SWHSI feasibility RCT. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-122.	1.0	0